Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function (JACC November 2023-1)

Description

SGLT-2 inhibitors are guideline-recommended in the management of heart failure (HF). While these therapies can be initiated even in patients with comorbid CKD, some patients may face deterioration in kidney function over time.

Editors
Editor-in-Chief
Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Author
Yevgeniy Khariton, MD, FACC

Important Dates
Date of Release: October 30, 2023
Term of Approval/Date of CME/MOC Expiration: October 29, 2024

Summary


Availability:	On-Demand
	Expires on Oct 29, 2024


Cost:	FREE


Credit Offered:	1 CME Credit 1 ABIM-MOC Point